A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Clinical trial NCT05330975 · COMPLETED

Trial details

NCT number: NCT05330975
Sponsor: ModernaTX, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus

Start date: 2022-04-01
Primary completion: 2024-11-08
Enrollment: 3317

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.